Definitions
LAE, left atrial enlargement; LVH, left ventricular hypertrophy.
References
1. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2022;79(17):e263-e421. doi:10.1016/j.jacc.2021.12.012
2. Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond). 2016;130(2):57-77. doi:10.1042/CS20150469
3. Menendez JT. The mechanism of action of LCZ696. Card Fail Rev. 2016;2(1):40-46. doi:10.15420/cfr.2016:1:1
4. Howell EH, Cameron SJ. Neprilysin inhibition: a brief review of past pharmacological strategies for heart failure treatment and future directions. Cardiol J. 2016;23(6):591-598. doi:10.5603/CJ.a2016.0063
5. Simmonds SJ, Cuijpers I, Heymans S, Jones EAV. Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding. Cells. 2020;9(1):242. doi:10.3390/cells9010242
6. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. doi:10.1002/ejhf.592
7. Toth PP, Gauthier D. Heart failure with preserved ejection fraction: disease burden for patients, caregivers, and the health-care system. Postgrad Med. 2021;133(2):140-145. doi:10.1080/00325481.2020.1842621
8. Røe ÅT, Sjaastad I, Louch WE. Heart failure with preserved ejection fraction. Tidsskr Nor Laegeforen. 2017;137(18). English, Norwegian. doi:10.4045/tidsskr.16.1068
9. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263-271. doi:10.1016/j.jacc.2013.02.092
10. Sabbah HN. Silent disease progression in clinically stable heart failure. Euro J Heart Fail. 2017;19:469-478. doi:10.1002/ejhf.7054
11. Gheorghiade N, De Luca L, Fonarow GC, et al. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96(suppl):11G-17G. doi:10.1016/j.amjcard.2005.07.016
12. Mesquita ET, Jorge AJL, Rabelo LM, Souza CV. Understanding hospitalization in patients with heart failure. Int J Cardio Sci. 2017;30(1):81-90. doi:10.5935/2359-4802.2016006
13. ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.